• Access to all necessary nuclear and GMP facilities
  • Nuclear R&D and operational expertise
  • Partnership representing the full expertise and capabilities
Our research focuses on the development of new radiopharmaceutical products, based on the availability of both high potential medical isotopes and dedicated nuclear infrastructure. We aim for products with a high possibility of adding value to nuclear medicine, more specifically for cancer treatment.

Straight to

  • Medical isotope in high demand
  • Beta-emitter
  • Independent supply from in-house FIELD-LAB process
More Information
  • High quality
  • Chemotherapeutic compound (cisplatin) with Pt-195m integrated by synthesis
  • For in-human use
  • Chemotherapeutic function unaltered
More Information
  • Beta-emitter with limited recoil, and a single alpha emission in the decay chain
  • Ideal half-life (~10 hrs.)
  • Reliable supply
More Information

Lead 212

Pb-212 is a medical isotope with great perspective for cancer therapy; the isotope offers maximal efficiency and minimal side effects.

Pb-212 has a half-life of 11 hours: long enough for targeting purposes, short enough and with a single alpha-emission to avoid long term, off-target damage.

Pb-212 production is complex and is difficult to get access to. FIELD-LAB has managed to achieve unlimited availability by developing its own, in-house production process. In addition, FIELD-LAB operates the facilities autonomously making it flexible in assigning resources and using this high potential isotope for R&D purposes.

Read more



Pt-195m CISSPECT is a promising imaging agent to measure the distribution of cisplatin chemotherapy in the patient. It can possibly be used to predict the effectivity of cisplatin treatment and/or to determine potential toxicity.

The prediction outcome can then serve as input to optimise the individual patient treatment and to determine whether cisplatin treatment is useful. Or if alternatives should be considered, due to expected severe side effects such as kidney failure, loss of hearing, nausea and tiredness.

Lu-177 chloride n.c.a.

Currently, Lu-177 is dominating the clinical pipeline regarding the innovation of radiopharmaceuticals. Researchers have found numerous possible applications for this radio isotope.

We are looking to provide bio pharma and scientific partners with Lu-177 chloride (n.c.a.) and support their pre-clinical and clinical studies in the development of Lu-177 radiopharmaceuticals. These partners can range from (academic) hospitals to commercial start-ups.


We add value to …

drag for more

The development of new nuclear medicine.

Knowledge transfer, from science to industry.

Upscaling opportunities.


The market for lutetium-177 is expected to grow significantly in the coming years. There are many products in the clinical pipeline that use lutetium-177 as radioactive substance, and we are seeing new, up-and-coming therapies. A promising agent is lutetium-177 PSMA, which acts on the prostate-specific membrane antigen and is used in the treatment of metastasised prostate cancer. In addition to prostate carcinomas, other cancers could be treated with the isotope lutetium-177 in the future. Prof. Hendrikse of Amsterdam UMC, VUmc location, foresees expanding possibilities for patient treatment despite some issues related to market availability.

04 February 2021

Medical isotope offers great perspective for the effective treatment of various cancer indications with limited side effects